ZeClinics Therapeutics is a biopharmaceutical company focused on the development of treatments for cardiovascular diseases. Nowadays cardiovascular diseases are the cause of death of at least a third of the global population. Despite this issue, there is not enough research on this area because all the focus is on fighting cancer.
ZeClinics proposes a revolutionary way to make new developments on the cardiovascular therapies, looking for treatments where there is no cure yet and treatments that only cure the symptoms but not the causes.
We at Inveniam congratulate ZeClinics for their hard work and we wish them the best of luck for the funding campaign throw Capital Cell. To find out more about their campaign and the benefits of becoming an investor watch the video down here and then go to https://capitalcell.es/campaign/zecardio/